Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
23 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-02-28
Study Completion Date
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Introduction:
Foot ulcers are a feared complication among diabetic patients. The ulcers can cause pain, discomfort and reduced quality of life. The development of foot ulcers places the patients at a risk of amputation. In the Danish Health Care System a substantial effort is done to prevent and treat diabetic foot ulcers. A constant research of how to treat these wounds is ongoing. The goal is to optimize wound healing and prevent amputations.
Extracorporeal shockwave therapy (ESWT) involves the use of a device that generates low-energy shockwaves through a headpiece, which is placed on the skin of the patient. A small amount of energy will be deposited in the tissue when shockwaves are applied. This stimulates the cells to produce substances that generate new vessels. No side effects to ESWT have been shown.
Purpose:
The investigators want to test whether shockwave therapy can improve wound healing among diabetic patients with foot ulcers.
Hypothesis:
The investigators hypothesize that shockwave therapy accelerates ulcer healing, increases blood flow, reduces pain, and has no side effects.
Method:
Patients who are interested in participation will be included in the study and divided by randomization into two groups of equal size. The first group is treated with ESWT in combination with regular guideline treatment. The second group is set up as control group and will only receive regular guideline treatment. The participants are examined in different ways to evaluate whether ESWT helps the healing of foot ulcers. The investigators want to measure tissue oxygen pressure and foot sense of touch. The foot ulcers are inspected for infection at every consultation, and a swab sample will be collected at enrollment. The size of the ulcers are measured and photographed each time. The investigators will count how many foot ulcers that are completely healed during the test period and measure the sizes of the remaining foot ulcers. The patients are asked to evaluate pain related to the foot ulcer. Data concerning participants' co morbidities and use of analgesic drugs are obtained from the patient journal and by patient interview.
Significance:
ESWT should be considered a supplement to existing clinical guidelines in wound management if shown to effectively help healing of diabetic foot ulcers. Improved healing should reduce the heavy workload on care and treatment regarding to these wounds. Hopefully, the frequency of amputations among diabetic patients will decline by implementing new treatment options for the diabetic foot.
Foot ulcers are a feared complication among diabetic patients. The ulcers can cause pain, discomfort and reduced quality of life. The development of foot ulcers places the patients at a risk of amputation. In the Danish Health Care System a substantial effort is done to prevent and treat diabetic foot ulcers. A constant research of how to treat these wounds is ongoing. The goal is to optimize wound healing and prevent amputations.
Extracorporeal shockwave therapy (ESWT) involves the use of a device that generates low-energy shockwaves through a headpiece, which is placed on the skin of the patient. A small amount of energy will be deposited in the tissue when shockwaves are applied. This stimulates the cells to produce substances that generate new vessels. No side effects to ESWT have been shown.
Purpose:
The investigators want to test whether shockwave therapy can improve wound healing among diabetic patients with foot ulcers.
Hypothesis:
The investigators hypothesize that shockwave therapy accelerates ulcer healing, increases blood flow, reduces pain, and has no side effects.
Method:
Patients who are interested in participation will be included in the study and divided by randomization into two groups of equal size. The first group is treated with ESWT in combination with regular guideline treatment. The second group is set up as control group and will only receive regular guideline treatment. The participants are examined in different ways to evaluate whether ESWT helps the healing of foot ulcers. The investigators want to measure tissue oxygen pressure and foot sense of touch. The foot ulcers are inspected for infection at every consultation, and a swab sample will be collected at enrollment. The size of the ulcers are measured and photographed each time. The investigators will count how many foot ulcers that are completely healed during the test period and measure the sizes of the remaining foot ulcers. The patients are asked to evaluate pain related to the foot ulcer. Data concerning participants' co morbidities and use of analgesic drugs are obtained from the patient journal and by patient interview.
Significance:
ESWT should be considered a supplement to existing clinical guidelines in wound management if shown to effectively help healing of diabetic foot ulcers. Improved healing should reduce the heavy workload on care and treatment regarding to these wounds. Hopefully, the frequency of amputations among diabetic patients will decline by implementing new treatment options for the diabetic foot.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Low Intensity Shockwave Therapy in Treating Diabetic Foot Ulcers
NCT02691234
Diabetic Foot Ulcers
UNKNOWN
PHASE1/PHASE2
Extracorporeal Shockwave Therapy for Diabetic Foot Wounds
NCT04042285
Diabetic Foot
Wound
COMPLETED
Shockwave Treatment of Diabetic Foot Ulcer: Step I
NCT00954343
Chronic Diabetic Foot Ulcers
WITHDRAWN
NA
Extracorporeal Shockwave Therapy for Diabetic Foot Ulcers
NCT05380544
Diabetic Foot
ACTIVE_NOT_RECRUITING
NA
Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers
NCT00366132
Chronic Diabetic Foot Ulcers
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\[Introduction\]
It is estimated that 5.5 % of the Danish population suffers from diabetes - corresponding to more than 320.000 persons. Among Danish diabetic patients the yearly incidence of foot ulcers is higher than 3.000 and the prevalence higher than 22.000. Diabetics have a lifetime risk of foot ulcers of 15 %.
Amputation is a possible consequence to having a diabetic foot ulcer. A 19-year follow-up study performed on newly diagnosed diabetics shows an incidence of amputation of 400 per 100.000 patient years.
Economical costs associated with a diabetic foot ulcer vary with the severity and treatment of the ulcer. In Denmark costs including hospitalized treatment, outpatient treatment, homecare and other social services have been calculated to (written in Danish kroner 2009):
* Healed foot ulcer without ischemia: 152.800
* Healed foot ulcer with ischemia: 252. 800
* Foot ulcer with minor amputation: 407.900
* Foot ulcer with major amputation: 597.300
Groups including foot ulcers with minor or major amputation comprise 5 % of the total number of diabetic foot ulcers (corresponding to 150 amputations per year). Total costs of diabetic foot ulcers are 793 million Danish kroner.
Foot ulcers reduce the patients' mobility and their quality of life. Amputation is among the most feared complications to diabetes and it affects patients' quality of life as much as heart failure and cerebral stroke.
The treatment of diabetic foot ulcers is in several places of Denmark taken care of by multidisciplinary teams. Thus metabolic control, wound debridement, vascular surgery, treatment of infections, pain relief, occupational therapy etc. is taken care of in one specialized hospital unit. Parallel to a reorganization of the Danish health system 2000 - 2011 there was a significant decline in diabetic major amputations. However, no decline has been seen in the group of minor amputations and it may be that patients are now identified earlier for amputation thereby avoiding major amputations. Conclusively, a number of diabetic ulcer patients still cannot be offered any other treatment than amputation.
It is important to develop supplementing treatment options for the worst cases of diabetic foot ulcers. The goal is that ulcer healing is optimized and fewer patients are amputated.
In the field of diabetic foot ulcers a substantial amount of research is going on trying to develop existing methods of treatment and finding new therapeutic techniques. Extracorporeal shockwave therapy (ESWT) is a promising new option for ulcer treatment. ESWT has long been known in kidney stone treatment, and more recently ESWT has been established as treatment to regional pain disorders (such as plantar fasciitis of the heel and lateral epicondylitis of the elbow) and non-union of long bone fractures. Furthermore, ischemic heart disease and Peyronies disease have been treated with ESWT. Some studies show positive results when treating foot ulcers with ESWT.
In physics, shockwaves are high fluctuations of acoustical energy. When applied to a tissue shockwaves may stimulate an anabolic cellular response, increased blood perfusion and neo-angiogenesis. Shockwaves may furthermore promote anti-inflammatory effects and pain regulation. On a molecular scale upregulation of TGF-beta1, VEGF, FGF-2 signaling together with increased levels of NO and substance P in the tissue is seen following ESWT. During wound healing NO has been shown to induce IGF release through NF-kappaB pathway. Regarding to anti-inflammatory effects, ESWT reduces the cellular expression of metalloproteases and interleukins.
Clinical studies testing foot ulcer ESWT have not shown any significant side effects to shockwave treatment. These studies conclude that ESWT is safe to use.
\----------------------------------------------------------------------------------------------------------------
\[Purpose\]
The investigators want to test if low-energy ESWT can help healing of complex diabetic foot ulcers. The effect of ESWT will be evaluated by measuring wound sizes and numbers of total healing, perception of pain using visual analog scale. Measures of cutaneous oxygen tension and foot sense of feeling will be included as well.
\----------------------------------------------------------------------------------------------------------------
\[Hypothesis\]
ESWT improves diabetic patients' healing of chronic foot ulcers. In this study the investigators expect to see a faster wound area reduction among patients treated with ESWT compared to control group only receiving treatment according to current clinical guidelines.
Primary outcome measure for ESWT is
* Shorter time wound healing
Secondary outcome measures for ESWT are
* Pain reduction
* Increased perfusion
* No side effects
\[Method\]
Recruitment of patients: 6 months consecutive identification and inclusion of patients in Wound Clinic, Department of Plastic Surgery OUH. Every year approximately 400 patients with new ulcers are referred to the clinic. Patients who are either newly referred or in advance related to the clinic can be offered participation.
Randomization: Participants will be randomized to either intervention group or control group using a computer-generated table indicating allocation.
Intervention group: ESWT as a supplement to treatment following current clinical guidelines.
Control group: Ulcer treatment following clinical guidelines.
ESWT: A total of 6 times treatment over a 3 week period. Intervals between ESWT will be 3 - 4 days. ESWT will be carried out using the DUOLITH SD1 T-Top shockwave device, STORZ MEDICAL AG. The device is CE mark registered for ESWT use.
Description of intervention course: Participants in this group will have 8 consultations in a 7 week period. 6 times ESWT followed by 2 times follow-up respectively 2 and 4 weeks after last ESWT.
Description of control course: Participants in this group will have 4 consultations in a 7 week period. First consultation by enrollment. Second, third, and fourth consultations respectively 3, 5, and 7 weeks after enrollment. These four consultations corresponds to intervention group consultation number 1, 6, 7, and 8.
Baseline data: By the first consultation participants will be characterized in regard to the following variables:
* Sex
* Age
* Comorbidity (quantified using Charlson Index)
* Medical treatment: antidiabetics, analgesics (relevant drugs are NSAIDs, neuroleptics and opioids), antihypertensives, statins / cholesterol lowering drugs
* Smoking habits and alcohol consumption
* Body Mass Index
* Marital status, educational level and type of profession
* Classification of foot ulcer using University of Texas Wound Score
* Biochemistry: HbA1c, CRP, leukocytes, s-Na, s-K, s-creatinine, s-alkaline phosphatase, s-lactate dehydrogenase, s-cholesterol levels
* Bacterial colonization of the ulcer
Biochemical parameters and medical treatment data will be obtained from the patient records. New blood samples will be taken if the patient records do not include relevant test results - furthermore results must not be more than 2 months old.
Patients enrolled in the study will have access to all usually offered ulcer treatment. Information about other treatment modalities and frequencies will be obtained from participants patient records and patient interviews.
\----------------------------------------------------------------------------------------------------------------
\[Data handling\]
Data will be noted in the REDCap online system. Data will be stored until study end. Analysis will be carried out using Stata software.
The study uses only one data collector who will also enter data in REDCap. However, if data are not available or missing, the specific measurements will be excluded from analysis. Missing data will be reported with published study results.
\----------------------------------------------------------------------------------------------------------------
\[Statistics\]
Average percentage reduction of ulcer area is the study's primary end-point. If data are normally distributed (determined by probit or logit plot) statistical analysis can be performed using Student's t-test. Non-normally distributed data can be analyzed using transformation of data or non-parametric statistics (Wilcoxon rank sum test or Mann-Whitney U-test). Other numerical data (cutaneous oxygen tension, pain scoring, use of analgesics) can be statistically evaluated in the same manner as ulcer area reduction.
Complete ulcer healing is regarded as binary end-point data. Healing proportions will be calculated and compared between intervention group and control group - risk ratio and confidence intervals will be determined. Significance of data will be tested using Pearson's chi-squared test (alternatively Fisher's exact test if data material is small / does not fit chi-test). Sense of touch data will be evaluated in the same way.
Comparison of patient's quality of life in intervention group and control group is based on average questionnaire scores.
\----------------------------------------------------------------------------------------------------------------
\[Study power\]
This study should be considered a pilot study. Earlier studies investigating ESWT ulcer treatment focus on study populations which are different from ours. The investigators consider our design to be unique since the investigators have not been able to identify earlier studies using a standard care control group to compare against intervention with 6 times ESWT in 3 weeks.
\----------------------------------------------------------------------------------------------------------------
\[Project feasibility\]
The project is carried out as an undergraduate research year in the period 1/9-2014 - 1/9-2015. Medical student Sune Møller Jeppesen is accepted as an undergraduate student from the Faculty of Health Science, University of Southern Denmark. The undergraduate student works under guidance from main supervisor Lars Lund, professor, MD, DMSci. Knud Bonnet Yderstræde, MD, PhD, and Benjamin Schnack Rasmussen, MD, PhD-student, are co-supervisors for the project. Primarily, the undergraduate student's work will involve ESWT consultations and data collection. The student will be trained in relevant techniques needed for measuring ESWT effects.
Office facilities are available for the undergraduate student at the Department of Urology. Consultation room and devices for clinical measurements are available at the Wound Clinic, Department of Plastic Surgery OUH. Shockwave device will be purchased (see budget information).
The project will be registered to relevant authorities including the Danish Data Protection Agency and the Committee for Health Research Ethics, Denmark.
\----------------------------------------------------------------------------------------------------------------
\[Publication\]
Trial results will be applied for publishing in an international scientific journal. Furthermore results will be presented at science conferences within the fields of interest.
\----------------------------------------------------------------------------------------------------------------
\[Economy\]
The investigators seek research funding from private and public organizations. The investigators apply for 120.000 Danish kroner (DKK) to cover 12 months undergraduate student salary and 371.125 DKK for shockwave device purchase. Costs related to office facilities are 14.500 DKK. Project overhead is 3 % of total costs. Total project costs are 520.794 DKK.
\----------------------------------------------------------------------------------------------------------------
\[Significance of the project\]
The project aims to evaluate healing effects of ESWT. If ESWT effectively can improve healing of complicated diabetic foot ulcers, ESWT should be considered for implementation in ulcer treatment clinical guidelines. Better ulcer healing can potentially improve patient's quality of life and decrease the number of diabetic patients who are being amputated (or at least postpone amputations). Later, research may be carried out to refine ulcer ESWT.
Proven ulcer healing effects of ESWT may also inspire future studies to test ESWT effects in the context of other clinical conditions. Possibly ESWT can be used in several settings where regenerative and anti-inflammatory effects are wanted.
It is estimated that 5.5 % of the Danish population suffers from diabetes - corresponding to more than 320.000 persons. Among Danish diabetic patients the yearly incidence of foot ulcers is higher than 3.000 and the prevalence higher than 22.000. Diabetics have a lifetime risk of foot ulcers of 15 %.
Amputation is a possible consequence to having a diabetic foot ulcer. A 19-year follow-up study performed on newly diagnosed diabetics shows an incidence of amputation of 400 per 100.000 patient years.
Economical costs associated with a diabetic foot ulcer vary with the severity and treatment of the ulcer. In Denmark costs including hospitalized treatment, outpatient treatment, homecare and other social services have been calculated to (written in Danish kroner 2009):
* Healed foot ulcer without ischemia: 152.800
* Healed foot ulcer with ischemia: 252. 800
* Foot ulcer with minor amputation: 407.900
* Foot ulcer with major amputation: 597.300
Groups including foot ulcers with minor or major amputation comprise 5 % of the total number of diabetic foot ulcers (corresponding to 150 amputations per year). Total costs of diabetic foot ulcers are 793 million Danish kroner.
Foot ulcers reduce the patients' mobility and their quality of life. Amputation is among the most feared complications to diabetes and it affects patients' quality of life as much as heart failure and cerebral stroke.
The treatment of diabetic foot ulcers is in several places of Denmark taken care of by multidisciplinary teams. Thus metabolic control, wound debridement, vascular surgery, treatment of infections, pain relief, occupational therapy etc. is taken care of in one specialized hospital unit. Parallel to a reorganization of the Danish health system 2000 - 2011 there was a significant decline in diabetic major amputations. However, no decline has been seen in the group of minor amputations and it may be that patients are now identified earlier for amputation thereby avoiding major amputations. Conclusively, a number of diabetic ulcer patients still cannot be offered any other treatment than amputation.
It is important to develop supplementing treatment options for the worst cases of diabetic foot ulcers. The goal is that ulcer healing is optimized and fewer patients are amputated.
In the field of diabetic foot ulcers a substantial amount of research is going on trying to develop existing methods of treatment and finding new therapeutic techniques. Extracorporeal shockwave therapy (ESWT) is a promising new option for ulcer treatment. ESWT has long been known in kidney stone treatment, and more recently ESWT has been established as treatment to regional pain disorders (such as plantar fasciitis of the heel and lateral epicondylitis of the elbow) and non-union of long bone fractures. Furthermore, ischemic heart disease and Peyronies disease have been treated with ESWT. Some studies show positive results when treating foot ulcers with ESWT.
In physics, shockwaves are high fluctuations of acoustical energy. When applied to a tissue shockwaves may stimulate an anabolic cellular response, increased blood perfusion and neo-angiogenesis. Shockwaves may furthermore promote anti-inflammatory effects and pain regulation. On a molecular scale upregulation of TGF-beta1, VEGF, FGF-2 signaling together with increased levels of NO and substance P in the tissue is seen following ESWT. During wound healing NO has been shown to induce IGF release through NF-kappaB pathway. Regarding to anti-inflammatory effects, ESWT reduces the cellular expression of metalloproteases and interleukins.
Clinical studies testing foot ulcer ESWT have not shown any significant side effects to shockwave treatment. These studies conclude that ESWT is safe to use.
\----------------------------------------------------------------------------------------------------------------
\[Purpose\]
The investigators want to test if low-energy ESWT can help healing of complex diabetic foot ulcers. The effect of ESWT will be evaluated by measuring wound sizes and numbers of total healing, perception of pain using visual analog scale. Measures of cutaneous oxygen tension and foot sense of feeling will be included as well.
\----------------------------------------------------------------------------------------------------------------
\[Hypothesis\]
ESWT improves diabetic patients' healing of chronic foot ulcers. In this study the investigators expect to see a faster wound area reduction among patients treated with ESWT compared to control group only receiving treatment according to current clinical guidelines.
Primary outcome measure for ESWT is
* Shorter time wound healing
Secondary outcome measures for ESWT are
* Pain reduction
* Increased perfusion
* No side effects
\[Method\]
Recruitment of patients: 6 months consecutive identification and inclusion of patients in Wound Clinic, Department of Plastic Surgery OUH. Every year approximately 400 patients with new ulcers are referred to the clinic. Patients who are either newly referred or in advance related to the clinic can be offered participation.
Randomization: Participants will be randomized to either intervention group or control group using a computer-generated table indicating allocation.
Intervention group: ESWT as a supplement to treatment following current clinical guidelines.
Control group: Ulcer treatment following clinical guidelines.
ESWT: A total of 6 times treatment over a 3 week period. Intervals between ESWT will be 3 - 4 days. ESWT will be carried out using the DUOLITH SD1 T-Top shockwave device, STORZ MEDICAL AG. The device is CE mark registered for ESWT use.
Description of intervention course: Participants in this group will have 8 consultations in a 7 week period. 6 times ESWT followed by 2 times follow-up respectively 2 and 4 weeks after last ESWT.
Description of control course: Participants in this group will have 4 consultations in a 7 week period. First consultation by enrollment. Second, third, and fourth consultations respectively 3, 5, and 7 weeks after enrollment. These four consultations corresponds to intervention group consultation number 1, 6, 7, and 8.
Baseline data: By the first consultation participants will be characterized in regard to the following variables:
* Sex
* Age
* Comorbidity (quantified using Charlson Index)
* Medical treatment: antidiabetics, analgesics (relevant drugs are NSAIDs, neuroleptics and opioids), antihypertensives, statins / cholesterol lowering drugs
* Smoking habits and alcohol consumption
* Body Mass Index
* Marital status, educational level and type of profession
* Classification of foot ulcer using University of Texas Wound Score
* Biochemistry: HbA1c, CRP, leukocytes, s-Na, s-K, s-creatinine, s-alkaline phosphatase, s-lactate dehydrogenase, s-cholesterol levels
* Bacterial colonization of the ulcer
Biochemical parameters and medical treatment data will be obtained from the patient records. New blood samples will be taken if the patient records do not include relevant test results - furthermore results must not be more than 2 months old.
Patients enrolled in the study will have access to all usually offered ulcer treatment. Information about other treatment modalities and frequencies will be obtained from participants patient records and patient interviews.
\----------------------------------------------------------------------------------------------------------------
\[Data handling\]
Data will be noted in the REDCap online system. Data will be stored until study end. Analysis will be carried out using Stata software.
The study uses only one data collector who will also enter data in REDCap. However, if data are not available or missing, the specific measurements will be excluded from analysis. Missing data will be reported with published study results.
\----------------------------------------------------------------------------------------------------------------
\[Statistics\]
Average percentage reduction of ulcer area is the study's primary end-point. If data are normally distributed (determined by probit or logit plot) statistical analysis can be performed using Student's t-test. Non-normally distributed data can be analyzed using transformation of data or non-parametric statistics (Wilcoxon rank sum test or Mann-Whitney U-test). Other numerical data (cutaneous oxygen tension, pain scoring, use of analgesics) can be statistically evaluated in the same manner as ulcer area reduction.
Complete ulcer healing is regarded as binary end-point data. Healing proportions will be calculated and compared between intervention group and control group - risk ratio and confidence intervals will be determined. Significance of data will be tested using Pearson's chi-squared test (alternatively Fisher's exact test if data material is small / does not fit chi-test). Sense of touch data will be evaluated in the same way.
Comparison of patient's quality of life in intervention group and control group is based on average questionnaire scores.
\----------------------------------------------------------------------------------------------------------------
\[Study power\]
This study should be considered a pilot study. Earlier studies investigating ESWT ulcer treatment focus on study populations which are different from ours. The investigators consider our design to be unique since the investigators have not been able to identify earlier studies using a standard care control group to compare against intervention with 6 times ESWT in 3 weeks.
\----------------------------------------------------------------------------------------------------------------
\[Project feasibility\]
The project is carried out as an undergraduate research year in the period 1/9-2014 - 1/9-2015. Medical student Sune Møller Jeppesen is accepted as an undergraduate student from the Faculty of Health Science, University of Southern Denmark. The undergraduate student works under guidance from main supervisor Lars Lund, professor, MD, DMSci. Knud Bonnet Yderstræde, MD, PhD, and Benjamin Schnack Rasmussen, MD, PhD-student, are co-supervisors for the project. Primarily, the undergraduate student's work will involve ESWT consultations and data collection. The student will be trained in relevant techniques needed for measuring ESWT effects.
Office facilities are available for the undergraduate student at the Department of Urology. Consultation room and devices for clinical measurements are available at the Wound Clinic, Department of Plastic Surgery OUH. Shockwave device will be purchased (see budget information).
The project will be registered to relevant authorities including the Danish Data Protection Agency and the Committee for Health Research Ethics, Denmark.
\----------------------------------------------------------------------------------------------------------------
\[Publication\]
Trial results will be applied for publishing in an international scientific journal. Furthermore results will be presented at science conferences within the fields of interest.
\----------------------------------------------------------------------------------------------------------------
\[Economy\]
The investigators seek research funding from private and public organizations. The investigators apply for 120.000 Danish kroner (DKK) to cover 12 months undergraduate student salary and 371.125 DKK for shockwave device purchase. Costs related to office facilities are 14.500 DKK. Project overhead is 3 % of total costs. Total project costs are 520.794 DKK.
\----------------------------------------------------------------------------------------------------------------
\[Significance of the project\]
The project aims to evaluate healing effects of ESWT. If ESWT effectively can improve healing of complicated diabetic foot ulcers, ESWT should be considered for implementation in ulcer treatment clinical guidelines. Better ulcer healing can potentially improve patient's quality of life and decrease the number of diabetic patients who are being amputated (or at least postpone amputations). Later, research may be carried out to refine ulcer ESWT.
Proven ulcer healing effects of ESWT may also inspire future studies to test ESWT effects in the context of other clinical conditions. Possibly ESWT can be used in several settings where regenerative and anti-inflammatory effects are wanted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetic Foot Ulcer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Extracorporeal shockwave therapy
6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
Group Type
EXPERIMENTAL
Extracorporeal shockwave therapy
Intervention Type
DEVICE
Control
Standard care treatment
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extracorporeal shockwave therapy
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
STORZ DUOLITH SD1 T-top shockwave device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients receiving care and treatment in OUH Wound Clinic (Odense University Hospital, Denmark) with a diabetic foot ulcer.
* Wagner groups 1 and 2 (Wagner Ulcer Classification System)
* Wagner groups 1 and 2 (Wagner Ulcer Classification System)
Exclusion Criteria
* Patients with an ulcer duration of less than 2 months
* Ulcer area less than 0,5 x 0,5 cm (or less than 0,25 cm2)
* Patients who have had vascular surgery performed within the past 2 months
* Patients who cannot give informed consent
* Patients who do not read or speak danish
* Wagner groups 3 and 4 (Wagner Ulcer Classification System)
* Ulcer area less than 0,5 x 0,5 cm (or less than 0,25 cm2)
* Patients who have had vascular surgery performed within the past 2 months
* Patients who cannot give informed consent
* Patients who do not read or speak danish
* Wagner groups 3 and 4 (Wagner Ulcer Classification System)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southern Denmark
OTHER
Sponsor Role
collaborator
Odense University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sune Moeller Jeppesen
Medical student
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lars Lund, Professor
Role: STUDY_DIRECTOR
Odense University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odense University Hospital
Odense, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Bruun C, Siersma V, Guassora AD, Holstein P, de Fine Olivarius N. Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity. Diabet Med. 2013 Aug;30(8):964-72. doi: 10.1111/dme.12196. Epub 2013 Apr 26.
Reference Type
BACKGROUND
Siersma V, Thorsen H, Holstein PE, Kars M, Apelqvist J, Jude EB, Piaggesi A, Bakker K, Edmonds M, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J, Schaper NC. Importance of factors determining the low health-related quality of life in people presenting with a diabetic foot ulcer: the Eurodiale study. Diabet Med. 2013 Nov;30(11):1382-7. doi: 10.1111/dme.12254. Epub 2013 Jul 15.
Reference Type
BACKGROUND
Vileikyte L. Psychosocial and behavioral aspects of diabetic foot lesions. Curr Diab Rep. 2008 Apr;8(2):119-25. doi: 10.1007/s11892-008-0022-1.
Reference Type
BACKGROUND
Goodridge D, Trepman E, Embil JM. Health-related quality of life in diabetic patients with foot ulcers: literature review. J Wound Ostomy Continence Nurs. 2005 Nov-Dec;32(6):368-77. doi: 10.1097/00152192-200511000-00007.
Reference Type
BACKGROUND
Alva M, Gray A, Mihaylova B, Clarke P. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ. 2014 Apr;23(4):487-500. doi: 10.1002/hec.2930. Epub 2013 Jul 11.
Reference Type
BACKGROUND
Hirai FE, Tielsch JM, Klein BE, Klein R. Ten-year change in self-rated quality of life in a type 1 diabetes population: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Qual Life Res. 2013 Aug;22(6):1245-53. doi: 10.1007/s11136-012-0245-0. Epub 2012 Aug 8.
Reference Type
BACKGROUND
Jorgensen ME, Almdal TP, Faerch K. Reduced incidence of lower-extremity amputations in a Danish diabetes population from 2000 to 2011. Diabet Med. 2014 Apr;31(4):443-7. doi: 10.1111/dme.12320. Epub 2013 Oct 21.
Reference Type
BACKGROUND
Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, Londahl M, Price PE, Jeffcoate WJ. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:119-41. doi: 10.1002/dmrr.2246.
Reference Type
BACKGROUND
Gottrup F, Apelqvist J. Present and new techniques and devices in the treatment of DFU: a critical review of evidence. Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:64-71. doi: 10.1002/dmrr.2242.
Reference Type
BACKGROUND
Wang CJ. Extracorporeal shockwave therapy in musculoskeletal disorders. J Orthop Surg Res. 2012 Mar 20;7:11. doi: 10.1186/1749-799X-7-11.
Reference Type
BACKGROUND
Zimpfer D, Aharinejad S, Holfeld J, Thomas A, Dumfarth J, Rosenhek R, Czerny M, Schaden W, Gmeiner M, Wolner E, Grimm M. Direct epicardial shock wave therapy improves ventricular function and induces angiogenesis in ischemic heart failure. J Thorac Cardiovasc Surg. 2009 Apr;137(4):963-70. doi: 10.1016/j.jtcvs.2008.11.006.
Reference Type
BACKGROUND
Kiyota H, Ohishi Y, Asano K, Hasegawa N, Madarame J, Miki K, Kato N, Kimura T, Ishiyama T, Maeda S, Shimomura T, Shiono Y, Miki J. Extracorporeal shock wave treatment for Peyronie's disease using EDAP LT-02; preliminary results. Int J Urol. 2002 Feb;9(2):110-3. doi: 10.1046/j.1442-2042.2002.00430.x. No abstract available.
Reference Type
BACKGROUND
Schaden W, Thiele R, Kolpl C, Pusch M, Nissan A, Attinger CE, Maniscalco-Theberge ME, Peoples GE, Elster EA, Stojadinovic A. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. J Surg Res. 2007 Nov;143(1):1-12. doi: 10.1016/j.jss.2007.01.009. Epub 2007 Sep 27.
Reference Type
BACKGROUND
Saggini R, Figus A, Troccola A, Cocco V, Saggini A, Scuderi N. Extracorporeal shock wave therapy for management of chronic ulcers in the lower extremities. Ultrasound Med Biol. 2008 Aug;34(8):1261-71. doi: 10.1016/j.ultrasmedbio.2008.01.010. Epub 2008 Apr 18.
Reference Type
BACKGROUND
Wang CJ, Kuo YR, Wu RW, Liu RT, Hsu CS, Wang FS, Yang KD. Extracorporeal shockwave treatment for chronic diabetic foot ulcers. J Surg Res. 2009 Mar;152(1):96-103. doi: 10.1016/j.jss.2008.01.026. Epub 2008 Mar 7.
Reference Type
BACKGROUND
Moretti B, Notarnicola A, Maggio G, Moretti L, Pascone M, Tafuri S, Patella V. The management of neuropathic ulcers of the foot in diabetes by shock wave therapy. BMC Musculoskelet Disord. 2009 May 27;10:54. doi: 10.1186/1471-2474-10-54.
Reference Type
BACKGROUND
Wang CJ, Wu RW, Yang YJ. Treatment of diabetic foot ulcers: a comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy. Diabetes Res Clin Pract. 2011 May;92(2):187-93. doi: 10.1016/j.diabres.2011.01.019. Epub 2011 Apr 6.
Reference Type
BACKGROUND
Romeo P, Lavanga V, Pagani D, Sansone V. Extracorporeal shock wave therapy in musculoskeletal disorders: a review. Med Princ Pract. 2014;23(1):7-13. doi: 10.1159/000355472. Epub 2013 Nov 5.
Reference Type
BACKGROUND
Frairia R, Berta L. Biological effects of extracorporeal shock waves on fibroblasts. A review. Muscles Ligaments Tendons J. 2012 Apr 1;1(4):138-47. Print 2011 Oct.
Reference Type
BACKGROUND
Notarnicola A, Moretti B. The biological effects of extracorporeal shock wave therapy (eswt) on tendon tissue. Muscles Ligaments Tendons J. 2012 Jun 17;2(1):33-7. Print 2012 Jan.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.ssi.dk/Sundhedsdataogit/Sundhedsvaesenet%20i%20tal/Specifikke%20omraader/Diabetes.aspx
Statens Serum Institut (SSI) is responsible for research-based health surveillance, rational use of IT in the Danish healthcare system and prevention and control of infectious diseases, biological threats and congenital disorders.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-ESWTULCER
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
NCT01011387
COMPLETED
NA
Enhanced Ultrasound Treatment of Chronic Wounds With Monitoring of Healing and Quality of Life Outcomes
NCT03041844
UNKNOWN
NA
Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy
NCT06721754
RECRUITING
NA
3D Camera - Telemedical Foot Ulcer Treatment
NCT01870934
UNKNOWN
The Regeneration Effects of Derma-PACE Shockwave in Chronic Diabetic Ulcers
NCT01219127
UNKNOWN
NA
Cutaneous Microcirculation After Extracorporeal Shock Wave Therapy
NCT02417779
COMPLETED
NA
Prevention of Secondary Foot Ulcers in Patients With Diabetes Using Systematic Measuring of Skin Temperature.
NCT01269502
COMPLETED
NA
Comparing the Expected Benefit of Extra-corporeal-shockwave Therapy (ESWT) Treatment to Standard Care in Treating Diabetic Foot Ulcers
NCT01499472
UNKNOWN
NA
A Study Measuring the Effectiveness of Combined Modulated Ultrasound and Electric Current Stimulation as an Adjunctive Treatment in Treating Diabetic Foot Ulcers
NCT03458286
UNKNOWN
NA
Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers
NCT02134132
COMPLETED
PHASE1/PHASE2
ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
NCT02211495
COMPLETED
NA
Extracorporeal Shockwave Treatment for Chronic Soft Tissue Wounds
NCT00545896
COMPLETED
PHASE2
Cold atmOspheric plaSMa Therapy Versus standArd Wound Care in Diabetic Foot and Venous Leg ulcerS
NCT07251426
NOT_YET_RECRUITING
NA
Shock Wave Versus Vacuum Assisted Closure on Chronic Diabetic Foot Ulcer
NCT05849701
COMPLETED
NA
Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy
NCT05076955
UNKNOWN
EARLY_PHASE1
Negative Pressure Wound Therapy in the Management of Diabetic Foot Ulcers
NCT04093635
UNKNOWN
Three-dimensional Measurements of Diabetic Foot Ulcers
NCT02423850
COMPLETED
Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study
NCT01580917
COMPLETED
Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs
NCT02866565
NOT_YET_RECRUITING
PHASE2
The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs
NCT03640988
TERMINATED
NA
TWB-103 for Treating Lower Limb Ulcers on Patients With DM
NCT03624023
COMPLETED
PHASE1/PHASE2
A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.
NCT05145439
COMPLETED
NA
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
NCT05579743
RECRUITING
NA
A Predictive Technology for Prevention of Diabetic Foot Ulcers
NCT04769115
COMPLETED
NA